Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 6/20 | 0.50 |
| ▸ | CES1 | P23141 | 6/20 | 0.50 |
| ▸ | BCHE | P06276 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | ALB | P02768 | 1/20 | 0.36 |
| ▸ | ERN1 | O75460 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.34 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.34 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | TTR | P02766 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
| ▸ | HTR2B | P41595 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL180426 | 0.87 | — | — | |
| Methyl Alcohol SCHEMBL27837385 | 0.84 | CES2 (0.52) | CES2CES1BCHEHPGDALB | |
| SCHEMBL20592890 | 0.84 | CES2 (0.43) | CES2CES1BCHEHPGDALB | |
| Fluoride SCHEMBL28287723 | 0.83 | CES2 (0.50) | CES2CES1BCHEHPGDALB | |
| SCHEMBL28011857 | 0.83 | CES2 (0.50) | CES2CES1BCHEHPGDALB | |
| Ammonia Solution, Strong SCHEMBL27938961 | 0.83 | CES2 (0.50) | CES2CES1BCHEHPGDALB | |
| Water SCHEMBL28100193 | 0.83 | CES2 (0.50) | CES2CES1BCHEHPGDALB | |
| Magnesium SCHEMBL6436089 | 0.83 | CES2 (0.50) | CES2CES1BCHEHPGDALB | |
| Hydrogen Sulfide SCHEMBL28308551 | 0.83 | CES2 (0.50) | CES2CES1BCHEHPGDALB | |
| Hydrochloric Acid SCHEMBL27691382 | 0.83 | CES2 (0.50) | CES2CES1BCHEHPGDALB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116916755-A | Materials and methods for extending the shelf life of food products | JP实验室公司 | 2023-10-20 | — | — | CN | claimed |
| CN-114230555-A | Preparation method of chlorantraniliprole | 江苏七洲绿色科技研究院有限公司 | 2022-03-25 | — | — | CN | disclosed |
| CN-113666827-B | Synthetic method of fluxapyroxad intermediate | 江苏七洲绿色科技研究院有限公司 | 2022-03-01 | — | — | CN | disclosed |
| CN-113666827-A | Synthetic method of fluxapyroxad intermediate | 江苏七洲绿色科技研究院有限公司 | 2021-11-19 | — | — | CN | disclosed |
| CN-105008378-B | The manufacturing method of cross-coupling catalysts and aromatic compound | 北兴化学工业株式会社 | 2018-05-18 | — | — | CN | disclosed |
| US-20170342324-A1 | BIMESOGENIC COMPOUNDS AND MESOGENIC MEDIA | MERCK PATENT GMBH (DE) | 2017-11-30 | — | — | US | disclosed |
| CN-105753644-A | Method for preparing polyfluorobiphenyl compound through one-kettle technology | 浙江九洲药业股份有限公司 | 2016-07-13 | — | — | CN | disclosed |
| EP-2349256-B1 | HETEROCYCLIC BENZIMIDAZOLES AS TRPM8 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2013-01-23 | — | — | EP | disclosed |
| US-8299066-B2 | Compounds having NPY Y5 receptor antagonistic activity | SHIONOGI & CO., LTD. (JP) | 2012-10-30 | — | — | US | disclosed |
| CN-102702044-A | Carbocyclic and heterocyclic arylsulfones as gamma secretase inhibitors | SCHERING CORP | 2012-10-03 | — | — | CN | disclosed |
| US-20110028468-A1 | COMPOUNDS HAVING NPY Y5 RECEPTOR ANTAGONISTIC ACTIVITY | Shinonogi & Co., Ltd (JP) | 2011-02-03 | — | — | US | disclosed |
| EP-2280000-A1 | COMPOUND HAVING NPY Y5 RECEPTOR ANTAGONIST ACTIVITY | Shionogi&Co., Ltd. (JP) | 2011-02-02 | — | — | EP | disclosed |
| WO-2010045166-A1 | HETEROCYCLIC BENZIMIDAZOLES AS TRPM8 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-04-22 | — | — | WO | disclosed |
| US-20100093788-A1 | HETEROCYCLIC BENZIMIDAZOLES AS TRPM8 MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-04-15 | — | — | US | disclosed |
| US-20090023917-A1 | Selective Estrogen Receptor Modulators for the Treatment of Vasomotor Symptoms | ELI LILLY AND COMPANY (US) | 2009-01-22 | — | — | US | disclosed |
| US-20080116419-A1 | Mesogenic Compounds, Liquid Crystal Medium and Liquid Crystal Display | MERCK PATENT GMBH (DE) | 2008-05-22 | — | — | US | disclosed |
| WO-2007123941-A2 | CHROMANE AND CHROMENE DERIVATIVES AND USES THEREOF | WYETH (US) | 2007-11-01 | — | — | WO | disclosed |
| EP-1709021-A1 | SELECTIVE ESTROGEN RECEPTOR MODULATORS FOR THE TREATMENT OF VASOMOTOR SYMPTOMS | ELI LILLY AND COMPANY (US) | 2006-10-11 | — | — | EP | disclosed |
| WO-2006079406-A1 | MESOGENIC COMPOUNDS, LIQUID CRYSTAL MEDIUM AND LIQUID CRYSTAL DISPLAY | MERCK PATENT GMBH (DE) | 2006-08-03 | — | — | WO | disclosed |
| WO-2005073204-A1 | SELECTIVE ESTROGEN RECEPTOR MODULATORS FOR THE TREATMENT OF VASOMOTOR SYMPTOMS | ELI LILLY AND COMPANY (US) | 2005-08-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093788-A1 | HETEROCYCLIC BENZIMIDAZOLES AS TRPM8 MODULATORS | TRPM8, TRPV1, TRPM6 | CES2 3531/4885CES1 3454/4885BCHE 3373/4885 |
| US-20090023917-A1 | Selective Estrogen Receptor Modulators for the Treatment of Vasomotor Symptoms | GPER1, ESR1, HSD17B11 | CES2 1734/4885CES1 621/4885BCHE 3410/4885 |
| US-20080116419-A1 | Mesogenic Compounds, Liquid Crystal Medium and Liquid Crystal Display | CRY1, CRY2, IK | CES2 3130/4885CES1 4581/4885BCHE 3663/4885 |
| US-20170342324-A1 | BIMESOGENIC COMPOUNDS AND MESOGENIC MEDIA | MTX1, S100A11, MCRS1 | CES2 3481/4885CES1 3939/4885BCHE 3314/4885 |
| US-20110028468-A1 | COMPOUNDS HAVING NPY Y5 RECEPTOR ANTAGONISTIC ACTIVITY | NPY5R, NPY1R, NPY2R | CES2 2523/4885CES1 2978/4885BCHE 2136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.